{'fraction_non_alphanumeric': 0.02564102564102564, 'fraction_numerical': 0.0, 'mean_word_length': 5.424657534246576, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacotherapy in Parkinson’s disease.

Pharmacotherapy in Parkinson’s disease is complex, with dopaminergic stimulation as its backbone. During the past decade only a few new drugs have been registered. However, progress has been made in clinical experience. Recent studies suggest better and longer efficacy of MAO-B inhibitors. Therapy of advanced stages of Parkinson’s disease remains a challenge as the therapeutic window narrows and motor complications prevail.